Identification of Anaphylactogenic Antibodies in Peanut Allergy

Launched by UNIVERSITY OF ZURICH · Jun 29, 2016

Keywords

ClinConnect Summary

This is an observational study led by the University of Zurich that looks at the immune system in people with peanut allergy. Researchers will analyze blood samples to identify and describe antibodies that recognize major peanut allergens. They will also try to isolate the immune cells that make these antibodies and copy the antibody genes so they can study peanut-specific antibodies in detail. This work is designed to help scientists better understand how the immune system reacts to peanut allergens.

About 100 people, ages 3 years and older, who have a history of peanut allergy or who test positive for peanut sensitization can participate, with informed consent. The study does not involve any treatment; participants simply provide blood samples for analysis. There is no expected direct benefit, but the effort could improve knowledge about peanut allergy. The study is enrolling by invitation and is planned to continue through late 2025. Blood samples may be kept for genetic research purposes, and the sponsor is the University of Zurich, with collaboration from the University Children’s Hospital, Zurich.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants have a described clinical history of peanut allergy and/or are sensitized to peanut allergens (as evidenced by positive skin prick test and allergen-specific IgE testing)
• • Male and female subjects older than 3 years
• • Written informed consent
• Exclusion Criteria:
• • age below three years
• • patients suffering from any disease where blood withdrawals might impact the patients' health status such as known anemia.